These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26593678)

  • 41. 5-Lipoxygenase inhibitors: a patent evaluation (WO2011161615).
    Buscató El; Proschak E
    Expert Opin Ther Pat; 2012 Jul; 22(7):843-6. PubMed ID: 22697185
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PKC alpha protein but not kinase activity is critical for glioma cell proliferation and survival.
    Cameron AJ; Procyk KJ; Leitges M; Parker PJ
    Int J Cancer; 2008 Aug; 123(4):769-79. PubMed ID: 18508315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery and characterization of novel allosteric FAK inhibitors.
    Iwatani M; Iwata H; Okabe A; Skene RJ; Tomita N; Hayashi Y; Aramaki Y; Hosfield DJ; Hori A; Baba A; Miki H
    Eur J Med Chem; 2013 Mar; 61():49-60. PubMed ID: 22819505
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protein kinase C isoforms in atherosclerosis: pro- or anti-inflammatory?
    Fan HC; Fernández-Hernando C; Lai JH
    Biochem Pharmacol; 2014 Mar; 88(2):139-49. PubMed ID: 24440741
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole-benzimidazole derivatives as potent Aurora A/B kinase inhibitors.
    Zheng Y; Zheng M; Ling X; Liu Y; Xue Y; An L; Gu N; Ji M
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3523-30. PubMed ID: 23664099
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).
    Seganish WM
    Expert Opin Ther Pat; 2016 Aug; 26(8):917-32. PubMed ID: 27310003
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of protein kinase C βII isoform ameliorates methylglyoxal advanced glycation endproduct-induced cardiomyocyte contractile dysfunction.
    Zhang L; Huang D; Shen D; Zhang C; Ma Y; Babcock SA; Chen B; Ren J
    Life Sci; 2014 Jan; 94(1):83-91. PubMed ID: 24269213
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
    Malínková V; Vylíčil J; Kryštof V
    Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Technology evaluation: ISIS-3521.
    Li K; Zhang J; Sirois P; Hu Y
    Curr Opin Mol Ther; 1999 Jun; 1(3):393-8. PubMed ID: 11713804
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pyrazole carboxamides and carboxylic acids as protein kinase inhibitors in aberrant eukaryotic signal transduction: induction of growth arrest in MCF-7 cancer cells.
    Persson T; Yde CW; Rasmussen JE; Rasmussen TL; Guerra B; Issinger OG; Nielsen J
    Org Biomol Chem; 2007 Dec; 5(24):3963-70. PubMed ID: 18043801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10).
    Cheung CH; Coumar MS; Chang JY; Hsieh HP
    Expert Opin Ther Pat; 2011 Jun; 21(6):857-84. PubMed ID: 21591849
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phosphoinositide 3-kinase α inhibitors: a patent review.
    Denny WA
    Expert Opin Ther Pat; 2013 Jul; 23(7):789-99. PubMed ID: 23488930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protein Kinase C- alpha/betaII, delta, and zeta/lambda involvement in ethanol-induced MAPK expression in vascular smooth muscle cells.
    Johnson AL; Goode GD; Mtshali C; Myles EL; Washington B
    Cell Mol Biol (Noisy-le-grand); 2007 May; 53(4):38-44. PubMed ID: 17531159
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential role of PKC isoforms in GnRH and phorbol 12-myristate 13-acetate activation of extracellular signal-regulated kinase and Jun N-terminal kinase.
    Dobkin-Bekman M; Rahamin-Ben Navi L; Shterntal B; Sviridonov L; Przedecki F; Naidich-Exler M; Brodie C; Seger R; Naor Z
    Endocrinology; 2010 Oct; 151(10):4894-907. PubMed ID: 20810567
    [TBL] [Abstract][Full Text] [Related]  

  • 56. c-MET kinase inhibitors: a patent review (2011 - 2013).
    Zhu K; Kong X; Zhao D; Liang Z; Luo C
    Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors.
    Liu N; Wang Y; Huang G; Ji C; Fan W; Li H; Cheng Y; Tian H
    Bioorg Chem; 2016 Apr; 65():146-58. PubMed ID: 26950400
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Danusertib, an aurora kinase inhibitor.
    Meulenbeld HJ; Mathijssen RH; Verweij J; de Wit R; de Jonge MJ
    Expert Opin Investig Drugs; 2012 Mar; 21(3):383-93. PubMed ID: 22242557
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis and biological evaluation of new pyrazol-4-ylpyrimidine derivatives as potential ROS1 kinase inhibitors.
    Abdelazem AZ; Al-Sanea MM; Park BS; Park HM; Yoo KH; Sim T; Park JB; Lee SH; Lee SH
    Eur J Med Chem; 2015 Jan; 90():195-208. PubMed ID: 25461320
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR-ABL kinase inhibitors.
    Hu L; Zheng Y; Li Z; Wang Y; Lv Y; Qin X; Zeng C
    Bioorg Med Chem; 2015 Jul; 23(13):3147-52. PubMed ID: 26022079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.